Goodyear Tire & Rubber Co vs Eli Lilly And Co — how do they compare? Goodyear Tire & Rubber Co trades at $4.68 (market cap $1.37B), while Eli Lilly And Co trades at $1,179.27 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 759.1× Goodyear Tire & Rubber Co's market cap, and Eli Lilly And Co pays a 0.59% dividend while Goodyear Tire & Rubber Co pays none. Which is the better fit depends on your goals — on Pluang, investors hold Goodyear Tire & Rubber Co for 57 Days and Eli Lilly And Co for 93 Days on average.
| GT | LLY | |
|---|---|---|
Market Cap | $1.37B | $1.04T |
Volume | 9,470,773 | 3,064,878 |
Sector | Consumer Cyclical | Health |
52-Week High | $10.54 | $1.28K |
52-Week Low | $4.66 | $799.57 |
Typical Hold Time | 57 Days | 93 Days |
Enterprise Value | $8.72B | $1.09T |
Dividend Yield | — | 0.59% |
Signals from Pluang's Aura AI — not financial advice
The Goodyear Tire & Rubber Company (GT) trades at $4.75, down 1.28% with a bearish technical outlook. The stock shows attractive valuation metrics with P/E of 4.69 and P/B of 0.48, but faces fundamental challenges including negative net income margin of -14.37% and ROE of -63.93%. Recent earnings showed mixed results with Q2 2026 beating expectations despite a loss, while the company executes a restructuring strategy focusing on premium EV tires.
GT presents a high-risk opportunity with significant upside potential given the $8.00 consensus price target, but investors face substantial execution risks amid ongoing restructuring, declining revenues, and persistent losses. The bearish technicals and mixed analyst sentiment (34.62% buy rating) suggest cautious optimism dependent on successful turnaround execution and margin improvement.
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →